Nymox to use NicAlert in U.K. smoking cessation program

By Elaine Rigoli

Tampa, Fla., July 28 - Nymox Pharmaceutical Corp. said its NicAlert product will be used in a large smoking-cessation study in collaboration with g-Nostics Ltd. in the United Kingdom.

The study will involve about 1,200 patients and 36 pharmacies assessing the clinical and cost-effectiveness of g-Nostics's pharmacogenetic smoking intervention, when used in a primary-care setting.

NicAlert will be used both for the initial measurement of cotinine levels in the subjects and to validate smoking status throughout the program, according to a news release.

"Curbing tobacco use is recognized as a major health priority in the U.K. and innovative strategies to help smokers quit are urgently needed. We believe that this study will help increase the exposure and profile of our tobacco exposure tests in the U.K.," said Brian Doyle, Nymox's senior manager for worldwide sales and marketing, in the release.

Nymox is a pharmaceutical company based in Hasbrouck Heights, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.